Anti-Inflammatory Efficacy of Product Containing “Skin Calm Complex” <i>in Vitro</i> Reconstructed Epidermis

Abstract

Atopic dermatitis is classified as a chronic inflammatory skin disease, which is characterized by alterations in barrier function and immune system of the skin. In a previous study, the efficacy of REPAVAR ATOPIC SKIN BODY CREAM EXTREME (a product containing "SKIN CALM COMPLEX") on the epidermal barrier structure was demonstrated. However, the product has also been formulated to improve inflammation and itching. The aim of this study is to analyze product effectiveness on skin inflammation and itching which is associated with atopic dermatitis, by quantification of IL-1α and IL-8 interleukins secreted by human keratinocytes from reconstructed epidermis by ELISA assay. Mature (aged 17 days) sample tissues were treated with pro-inflammatory agents (PBS 1X and LPS) and with the product containing synergistic mix from plants extracts and Dihydroavenanthramide D, among other ingredients ("SKIN CALM COMPLEX") for 24 hours. Measuring the amounts of interleukins by ELISA assay showed 1) decreased levels of IL-1α and 2) no differences about IL-8 secretion. Product REPAVAR ATOPIC SKIN BODY CREAM EXTREME has an antiinflammatory effect on the release of pro-inflammatory cytokines, becoming an effective preventive agent on inflammation and itching due to maintenance and improvement of the keratinocyte epidermal structure.

An ex vivo skin model to probe modulation of local cutaneous arachidonic acid inflammation pathway

“…The European Union Reference Laboratory for Alternatives to Animal Testing (EC-VAM) introduced validated test tests for acute irritation potential from exposure to acutely irritant substances contained in various products using EpiSkin, EpiDerm SIT, Modified Epiderm and SkinEthic models (ECVAM). Studies on the activity of pro-inflammatory cytokines such as interleukins have been reported [33][34][35][36]. However, we were unable to locate literature reports on the use of these materials for determination of modulation of the AA inflammation pathway, the key target of topically delivered NSAIDs.…”